Therapix Biosciences

03.03.2017 | IPO

 ZAG-S&W represented Therapix Biosciences in $13.8 Million Initial Public Offering

Therapix is a specialty clinical-stage pharmaceutical company focused on technologies and assets based on cannabinoid pharmaceuticals.

The ZAG-S&W team consisted of attorneys from Boston, New York and Tel Aviv, including Howard Berkenblit, Oded Har-Even and David Huberman, as well as Shy Baranov, Rob Condon, Ron Ben-Bassat, Boaz Shiffman, Adi Israel and Hila Nahum represented them in this initial offering.

Recent Activity